These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25087891)

  • 1. FondaKIDS II: long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events.
    Ko RH; Michieli C; Lira JL; Young G
    Thromb Res; 2014 Sep; 134(3):643-7. PubMed ID: 25087891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FondaKIDS III: A long-term retrospective cohort study of fondaparinux for treatment of venous thromboembolism in children.
    Shen X; Wile R; Young G
    Pediatr Blood Cancer; 2020 Aug; 67(8):e28295. PubMed ID: 32307822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of fondaparinux in the prevention of venous thromboembolism in elderly medical patients: results of a single-center, retrospective study.
    Silvestri F; Pasca S; Labombarda A; Barbi A; Desideri M; Guidi P; Rogato A; Zaramella M; Bergamo M; Ageno W; Barillari G
    Minerva Med; 2014 Jun; 105(3):221-8. PubMed ID: 24988087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fondaparinux for prevention of venous thromboembolism in high-risk trauma patients: a pilot study.
    Lu JP; Knudson MM; Bir N; Kallet R; Atkinson K
    J Am Coll Surg; 2009 Nov; 209(5):589-94. PubMed ID: 19854398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study.
    Mismetti P; Samama CM; Rosencher N; Vielpeau C; Nguyen P; Deygas B; Presles E; Laporte S;
    Thromb Haemost; 2012 Jun; 107(6):1151-60. PubMed ID: 22476471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fondaparinux in the initial and long-term treatment of venous thromboembolism.
    Pesavento R; Amitrano M; Trujillo-Santos J; Di Micco P; Mangiacapra S; López-Jiménez L; Falgá C; García-Bragado F; Piovella C; Prandoni P; Monreal M;
    Thromb Res; 2015 Feb; 135(2):311-7. PubMed ID: 25543161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of fondaparinux for the prophylaxis of venous thromboembolism after resection for colorectal cancer.
    Tsutsumi S; Yajima R; Tabe Y; Takaaki T; Fujii F; Morita H; Kigure W; Kato T; Yamauchi H; Suto T; Asao T; Kuwano H
    Hepatogastroenterology; 2012; 59(120):2477-9. PubMed ID: 23169180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age.
    Young G; Yee DL; O'Brien SH; Khanna R; Barbour A; Nugent DJ
    Pediatr Blood Cancer; 2011 Dec; 57(6):1049-54. PubMed ID: 21319285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
    Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
    J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.
    Monagle P; Lensing AWA; Thelen K; Martinelli I; Male C; Santamaría A; Samochatova E; Kumar R; Holzhauer S; Saracco P; Simioni P; Robertson J; Grangl G; Halton J; Connor P; Young G; Molinari AC; Nowak-Göttl U; Kenet G; Kapsa S; Willmann S; Pap AF; Becka M; Twomey T; Beyer-Westendorf J; Prins MH; Kubitza D;
    Lancet Haematol; 2019 Oct; 6(10):e500-e509. PubMed ID: 31420317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of patients receiving long-term fondaparinux for thrombotic antiphospholipid syndrome.
    Bor B; Doyle AJ; Bartoli-Abdou JK; Hackett A; Collings V; Omrani F; Foskett C; Wareing A; Young J; Breen KA; Hunt BJ
    Lupus; 2024 Nov; 33(13):1446-1454. PubMed ID: 39283750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily fondaparinux monotherapy without warfarin for long-term treatment of venous thromboembolism.
    Shetty R; Seddighzadeh A; Parasuraman S; Vallurupalli NG; Gerhard-Herman M; Goldhaber SZ
    Thromb Haemost; 2007 Dec; 98(6):1384-6. PubMed ID: 18064344
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry.
    Beyer-Westendorf J; Lützner J; Donath L; Radke OC; Kuhlisch E; Hartmann A; Weiss N; Werth S
    J Thromb Haemost; 2012 Oct; 10(10):2045-52. PubMed ID: 22882706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism.
    O'Brien SH; Kulkarni R; Wallace A; Hamblin F; Burr S; Goldenberg NA
    J Thromb Haemost; 2014 Nov; 12(11):1822-5. PubMed ID: 25182454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Hillis C; Crowther MA
    Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.
    Cohen AT; Davidson BL; Gallus AS; Lassen MR; Prins MH; Tomkowski W; Turpie AG; Egberts JF; Lensing AW;
    BMJ; 2006 Feb; 332(7537):325-9. PubMed ID: 16439370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials.
    Eikelboom JW; Quinlan DJ; O'Donnell M
    Circulation; 2009 Nov; 120(20):2006-11. PubMed ID: 19884469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of venous thromboembolism prophylaxis with fondaparinux in ischemic stroke.
    Hackett CT; Ramanathan RS; Malhotra K; Quigley MR; Kelly KM; Tian M; Protetch J; Wong C; Wright DG; Tayal AH
    Thromb Res; 2015 Feb; 135(2):249-54. PubMed ID: 25554497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of low-dose fondaparinux (1.5 mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR study.
    Ageno W; Riva N; Noris P; Di Nisio M; La Regina M; Arioli D; Ria L; Monzani V; Cuppini S; Lupia E; Giorgi Pierfranceschi M; Dentali F;
    J Thromb Haemost; 2012 Nov; 10(11):2291-7. PubMed ID: 22925036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.